Ervebo Vaccine Provides Cross-Protection Against Bundibugyo Virus Infection in Macaques
The 2026 Bundibugyo virus (BDBV) disease outbreak in the Democratic Republic of the Congo (DRC) was declared a public health emergency (PHEIC) in May 2026 (1). Regional security concerns, debilitated medical infrastructure, diagnostic limitations, and lack of approved BDBV–specific medical countermeasures have contributed to rapid escalation of the outbreak (2). Currently, there are no licensed medical countermeasures for BDBV (3). Several BDBV-specific vaccines are in development (4), including a vesicular stomatitis virus (VSV)–based vaccine expressing the BDBV glycoprotein which has demonstrated strong preclinical efficacy (5-7); however, these candidates have not yet completed clinical evaluation. A licensed VSV-based vaccine expressing the Ebola virus glycoprotein (VSV-EBOV) (8) is available for human use and clinical (ERVEBO) and research grade (VSV-EBOV) material has been shown to elicit cross-reactive, cross-neutralizing and inconclusive cross-protective immune responses against the related BDBV (5,9-14). ERVEBO’s protective efficacy against BDBV, however, has not been formally established in the standard macaque model of BDBV infection. Macaques received a single human dose of ERVEBO or an unrelated VSV-based control vaccine and were challenged with BDBV 14 days after vaccination. ERVEBO vaccinated macaques exhibited significantly reduced clinical disease and strikingly increased survival, as well as significantly reduced viremia, mucosal viral shedding and disease-associated biochemistry markers consistent with protection against BDBV-mediated hepatorenal disease. These findings indicate that ERVEBO can rapidly mediate cross-protective immunity against BDBV.
Authors
- Kyle Lee O’Donnell (ORCID: https://orcid.org/0000-0002-7183-1966)
- Ekaterina S Altynova (ORCID: https://orcid.org/0000-0001-7544-2303)
- Kyle Rosenke (ORCID: https://orcid.org/0000-0001-8101-4348)
- Thomas Tipih (ORCID: https://orcid.org/0000-0003-3845-1942)
- Hannah van Riel
- Shanna Brown
- Chad S. Clancy (ORCID: https://orcid.org/0000-0002-5354-9270)
- Heinz Feldmann (ORCID: https://orcid.org/0000-0001-9448-8227)
- Atsuhi Okumura
- Andrea Marzi (ORCID: https://orcid.org/0000-0003-0186-9587)
- Paige Fletcher (ORCID: https://orcid.org/0000-0001-6860-305X)
- ANANDHI KANNAN
- Trenton Bushmaker (ORCID: https://orcid.org/0000-0002-2161-4808)
- Aaron Carmody (ORCID: https://orcid.org/0000-0003-4772-763X)
- Axel T. Lehrer (ORCID: https://orcid.org/0000-0002-0518-203X)
- Akash Rajeev
- Amanda Griffin
- Samantha Ertl
- Vignesh Mariappan
- Brian Smith
Institutions
- University of Hawaiʻi at Mānoa (US)
- National Institutes of Health (US)
- National Institute of Allergy and Infectious Diseases (US)
- Rocky Mountain Laboratories (US)
Publication Details
- Journal
- Research Square
- Published
- 2026-11-19
- DOI
- https://doi.org/10.21203/rs.3.rs-11694971/v1
- Primary Topic
- Viral Infections and Outbreaks Research
- Type
- preprint